CV Lattes
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Instituto Butantan (Institutional affiliation from the last research proposal) Birthplace: Brazil
Bachelor in Biomedical Sciences Universidade Estadual Paulista Júlio de Mesquita Filho - UNESP. Master degree and PhD in Sciences - Pharmacolog, Institute of Biomedical Sciences of the University of São Paulo. Postdoctoral at the Department of Chemistry and Systems Biology, School of Medicine, Stanford, USA. She was a visiting researcher in the Department of Anesthesia at Stanford University. Coordinator of the Junior Scientist Program at the Butantan Institute. He holds an MBA in Health Innovation Management from the Butantan Institute. Currently, she is a senior researcher at the Special Laboratory of Pain and Signaling (LEDS), where she conducts research in the area of pain, neuroinflammation and opioids. Advisor at the Interunit Graduate Programs in Biotechnology at the University of São Paulo and Toxinology at the Butantan Institute. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Human-induced pluripotent stem cells (iPSC) are promising for modeling diseases in individual human genetic backgrounds thus, for developing precision medicine. Also, their pluripotency allows them to be differentiated into diverse cell types. Previously, we showed that the neuroblastoma SH-SY5Y cell line is successfully differentiated into sensory neuron-like cells, expressing critical p…
Chronic and abusive alcohol consumption is a public health problem that affects 76.3 million individuals worldwide and is directly related to several pathologies, including alcoholic neuropathy. Alcoholic neuropathy is a chronic condition characterized by axonal degeneration of sensory and motor nerve fibers, which results in motor deficit, sensory changes, including chronic hypernocicept…
CENTD's focus is to combine the expertise of researchers at the Butantan Institute (biochemistry, OMICS, molecular and cellular biology, pharmacology, genetics, bioinformatics, immunology, and in vitro and in vivo assays) with GSK's experience in the search and validation of new targets related to immune-inflammatory diseases, to enable the design and development of new therapeutic agents…
Paclitaxel is a chemotherapy drug widely used to eliminate breast and ovarian cancer. Despite being effective against cancer cells, this chemotherapy induces neuropathy in about 70% of the patients. So far, little is known about the mechanisms involved in paclitaxel-induced neuropathy and the treatment is often ineffective or non-existent. Mitochondria are critical organelles to supply th…
Adequate control of neuropathic pain is still a challenge and an unmet clinical need. In addition, adverse effects and rapid development of tolerance have been associated to some of the drugs currently used for the treatment of pain, evidencing the need for new analgesic substances. Aldehyde-dehydrogenase 2 (ALDH-2) is a mitochondrial enzyme responsible for the metabolism of toxic aldehyd…
(Only some records are available in English at this moment)
Our research group focuses on identifying and validating molecular targets with anti-inflammatory and/or anti-nociceptive potential. To this end, peptides derived from venoms, aswell as extracts and secretions from various animals are used.Through the application of advanced techniques such as transcriptomics, proteomics, andchemoproteomics, novel molecular targets were identified. To inv…
The in vitro screening of natural and synthetic peptides derived from animal venoms to evaluate their cytoprotective and anti-inflammatory activities has contributed to the discovery of new pharmacological targets and the elucidation of pain and inflammation signaling pathways. Together with chemoproteomics assays, several peptides derived from Lonomia obliqua and Amblyomma cajennense wer…
(Only some records are available in English at this moment)
Chronic and abusive alcohol consumption is a public health problem that affects 76.3 million individuals worldwide and is directly related to several pathologies, including alcoholic neuropathy. Alcoholic neuropathy is a chronic condition characterized by axonal degeneration of sensory and motor nerve fibers, which results in motor deficit, sensory changes, including chronic hypernocicept…
Paclitaxel is a chemotherapeutic widely used to treat breast and ovarian cancer. Despite its efficacy against cancer cells, this drug triggers neuropathy in about 70% of the patients. So far, it is known that this drug induces microtubule stabilization and interrupts the axonal transport, leading to ATP impairment and increased oxidative stress. Studies demonstrate a causal correlation be…
(Only some records are available in English at this moment)
Chronic opioids often lead to tolerance and paradoxical hyperalgesia, limiting therapeutic efficacy. Transient receptor potential ankyrin 1 (TRPA1) ion channels, activated by reactive aldehydes, such as 4-hydroxynonenal (4-HNE), are involved in nociceptive signaling. Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme responsible for 4-HNE detoxification. Previous data have shown t…
Advanced glycation end products (AGEs) are proteins or lipids that irreversibly bindto sugar molecules and are consistently associated with the development of peripheralneuropathy and pain. In fact, sensory neurons gain pro-nociceptive functions whenexposed to AGEs. However, the direct effect of AGEs in neuronal and non-neuronalcells together with neuromuscular junctions is unknown. Organ…
Opioids are effective analgesics for treating moderate to severe pain, however, chronic opioid use results in the development of opioid tolerance. This tolerance to opioids causes the need over time for increased doses of opioids to achieve the same pain-relieving effect. Clinical evidence suggests that East Asians are more responsive to opioids and possibly resistant to opioid tolerance…
| 3 / 3 | Ongoing grants |
| 4 / 4 | Completed research grants |
| 6 / 6 | Ongoing scholarships in Brazil |
| 10 / 9 | Completed scholarships in Brazil |
| 2 / 2 | Ongoing scholarships abroad |
| 1 / 1 | Completed scholarships abroad |
| 26 / 25 | All research grants and scholarships |
| Associated processes | |